Showing 3491-3500 of 5842 results for "".
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Obesity and Epidermal Innate Immunity Linked to Resistance to Biologic Therapy in Psoriasishttps://practicaldermatology.com/news/obesity-and-epidermal-innate-immunity-linked-to-resistance-to-biologic-therapy-in-psoriasis/2473927/Patients with severe plaque psoriasis who are overweight are more likely to experience resistance to biologic therapies, according to new findings The study researchers designed and conducted a cross-sectional study at Gachon
- Continuous Abrocitinib Use Linked to Better Long-Term AD Outcomes: Studyhttps://practicaldermatology.com/news/continuous-abrocitinib-use-linked-to-better-long-term-ad-outcomes-study/2473925/A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic dermatitis (AD). "Although c
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline
- Rituximab Efficacious for Epidermolysis Bullosa Acquisita: Analysishttps://practicaldermatology.com/news/rituximab-shows-promise-for-epidermolysis-bullosa-acquisita/2473835/Data from a new systematic review indicate rituximab (RTX) may potentially be an effective treatment option for epidermolysis bullosa acquisita (EBA). Due to its chronic nature, management of EBA remains challenging, with remission and flare-up
- Dr. Raj Chovatiya: Lebrikizumab Long-Term Data Makes 'Night and Day' Differencehttps://practicaldermatology.com/news/Dr-Raj-Chovatiya-Lebrikizumab-Long-Term-Data-Makes-Night-Day-Difference/2471865/New long-term results presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showed complete skin clearance (EASI-100 or IGA 0) at 3 years in patients with moderate-to-severe atopic dermatitis taking lebrikizumab (EBGLYSS™, Eli Lilly and Company) in the AD
- Registration Opens for the Tell-All Tribune and Genesis Meetingshttps://practicaldermatology.com/news/Registration-Opens-Tell-All-Tribune-Genesis-Meetings/2471850/Registration is open for two Modern Aesthetics meetings that were overwhelmingly popular in 2024 and now will be held on the same weekend, June 20-21, at the W Hotel in Fort Lauderdale, Florida. The Tell-All Tribune: An Aesthetic Think Tank, which was an invitation-only event in its inaugu
- riSCC App Launched for Risk Stratification of cSCChttps://practicaldermatology.com/news/riSCC-App-Launched-Risk-Stratification-cSCC/2471817/The not-for-profit organization Skin Cancer Consortium Outcomes (SCOUT) announced it has launched riSCC, a data-driven clinician mobile app designed for risk stratification of cutaneous squamous cell carcinoma (cSCC) in clinical settings. SCOUT, founded in 2018, is committed to transformi
- Almirall Hosts 16th Skin Academyhttps://practicaldermatology.com/news/Almirall-Hosts-16th-Skin-Academy/2471810/Almirall held the 16th edition of its Skin Academy conference for healthcare professionals in the field of dermatology on March 22-23 at the Barcelona International Convention Center in Spain. The event featured a comprehensive program aimed at sharing state-of-the-art scientific knowledge
- Andrew Weinstein Voted AAD President-Electhttps://practicaldermatology.com/news/Andrew-Weinstein-Voted-AAD-President-Elect/2471798/Andrew H. Weinstein, MD, MPH, FAAD, was voted president-elect of the American Academy of Dermatology (AAD), the organization announced. Dr. Weinstein will be joined by vice president-elect Thomas E. Rohrer, MD, FAAD. Newly elected members of the board of directors are Alina G. Bridges, DO,